IPI-926: Phase Ib/II started

Infinity said investigators began an open-label, U.S. Phase Ib/II trial to evaluate 130-160 mg/day oral IPI-926 in combination with FOLFIRINOX (5-fluorouracil (5-FU), leucovorin, irinotecan, and oxali...